Other Vaccines - Portugal

Portugal

Highlights

In Portugal, the revenue in the Other Vaccines market is projected to reach US$106.80m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 10.62%, resulting in a market volume of US$176.90m by 2029.
When comparing globally, United States is anticipated to generate the highest revenue of US$24.73bn in 2024.
Portugal is experiencing an increase in demand for other vaccines due to a growing awareness of the importance of preventive healthcare.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Portugal is showing signs of growth and development in recent years.

Customer preferences: There is a growing awareness among Portuguese citizens about the importance of vaccination and the need to protect against a range of diseases. As a result, there has been an increase in demand for other vaccines beyond the traditional ones. Customers are looking for vaccines that can protect them from a range of illnesses, including those that are not covered by the national vaccination program.

Trends in the market: The Other Vaccines market in Portugal has seen a shift towards preventive healthcare and wellness. This has led to an increase in demand for vaccines that can help prevent the onset of diseases. There has also been a growing trend towards personalized medicine, with customers looking for vaccines that are tailored to their specific needs. This has led to an increase in the development of new vaccines that target specific diseases or population groups.

Local special circumstances: Portugal has a well-developed healthcare system that provides universal coverage to its citizens. The country has a high level of health literacy, which has contributed to the growing demand for other vaccines. Additionally, Portugal has a large elderly population, which is particularly vulnerable to a range of diseases. This has led to an increase in demand for vaccines that can protect against illnesses such as pneumonia and shingles.

Underlying macroeconomic factors: The Portuguese economy has been growing steadily in recent years, which has led to an increase in disposable income. This has made it easier for customers to access healthcare services, including vaccines. Additionally, the government has been investing in the healthcare sector, which has led to an increase in the availability of vaccines. The country's strategic location has also made it an attractive destination for pharmaceutical companies looking to expand their operations in Europe. This has led to an increase in the development and availability of other vaccines in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.